ORGO vs PATH · rev $482.0M vs P/E 19, rev $1.61B
Organogenesis Holdings Inc (ORGO) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Organogenesis Holdings Inc (ORGO) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported ORGO revenue for 2024-12-31 was $482.0M. Net income was $861.0K. Revenue was up 11.3% from 2023-12-31 to 2024-12-31. ORGO currently screens at market cap $301.1M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
ORGO currently screens at market cap $301.1M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the ORGO and PATH stock pages for the full models.
Not investment advice.